Full text is available at the source.
Abstract
Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), could provide significant benefits in managing metabolic diseases.
- GLP-1 RAs may lead to sustained weight loss in patients.
- These therapies are associated with improvements in various metabolic parameters.
- GLP-1 RAs could also reduce cardiovascular risk in individuals with metabolic disorders.
- Current cardiometabolic prevention strategies remain suboptimal despite advancements in pharmacotherapy.
Simplified